2016 Program Booklet

PAMS_Pamietnik_2016_Organization_PAMS 2/1/2016 12:40 PM Page 16
Jarosław Maciejewski
P
rofessor Jaroslaw Maciejewski is Chairman of Translational
Hematology and Oncology Research at the Taussig Cancer Institute,
Cleveland Clinic, Case Western University and Associate Director
of the Case Comprehensive Cancer Center (CCCC),
Cleveland, Ohio. He is board certified in internal medicine and hematology.
Dr. Maciejewski graduated from Humboldt University Medical School
(Charite) in Berlin, Germany, where he also received his doctorate. For his
doctoral research he received the Robert Koch Award of the Humboldt University.
He completed his internal medicine residency at the University of
Nevada, School of Medicine in Reno, NV and Hematology Fellowship at
the National Institutes of Health (NIH) Medical Center, Bethesda, MD.
He continued his postdoctoral research at the Hematology Branch of the National Heart, Lung and Blood Institute
(NHLBI) in Bethesda, MD before joining the Cleveland Clinic in 2001 as Section Head of Experimental
Hematology. In January 2009, Dr. Maciejewski was appointed Chairman of the newly-created
Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute. His clinical
areas of expertise include bone marrow failure syndromes, aplastic anemia, and myeloid malignancies. His
research deals with the molecular pathogenesis of these disorders, various aspects of stem-cell biology, genetics,
cytogenetics and immunobiology. He has developed multiple whole-genome scanning technologies for
laboratory and diagnostic use, including SNP arrays, methylation arrays and viral chips.
Dr. Maciejewski’s distinguished track record in hematology research has resulted in an extensive list of publications
(over 300 peer-reviewed journal articles and book chapters). As Principal Investigator, Dr. Maciejewski
has acquired notable grant funding from federal, foundation and industry sponsors. Since joining
the Cleveland Clinic in 2001 he has received 50 research grants ranging from $20,000 to $ 2,500,000, 23 of
them from NIH. His most recent NIH grant is a $1,000,000 Transformative R01 program. The Transformative
R01 grants are awarded for "exceptionally innovative, high-risk and unconventional research projects
that have the potential to create or overturn fundamental paradigms.” This funding will help support Dr. Maciejewski’s
research related to whether viruses could be the cause of certain types of bone-marrow cancers
and other blood disorders. In addition to bench translational research, he leads the Cleveland Clinic Bone
Marrow Failure Program that conducts clinical trials based on investigator-initiated protocols involving the
application of targeted immune therapies.
Dr. Maciejewski has received many other awards - Sam and Maria Miller Excellence in Research Award,
Leadership in Science Award, Excellence in Science Award, Celgene Young Investigator Award for Clinical
Research in Hematology, to name a few. He is a Fellow of the American College of Physicians, elected
Member of the American Society of Clinical Investigation, Chairman of the Scientific Committee on Myeloid
Neoplasia of the American Society of Hematology, serves on the Medical Advisory Board of the International
Aplastic Anemia and Myelodysplastic Syndrome Foundation and the editorial boards of BLOOD and
LEUKEMIA. He has also been a reviewer on various study sections for the NIH.
He is a sought-after speaker; during the last 10 years he has delivered over 100 invited lectures in the US,
Japan, Australia, Spain, Switzerland, Germany, Austria, Greece, England, France and Canada. Of note –
within the last five years he has been invited six times to lecture at Chicago-area universities. During the
same time he has to his credit over 150 presentations at scientific meetings.
Dr. Maciejewski is also committed to his role as mentor. His K24 Career Development award from the NIH
has enabled him to actively train over 60 graduate, postdoctoral, clinical and international fellows and junior
faculty through his Bone Marrow Failure Training Program for physician-scientists, and to mentor medical
students.
23